| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e7b8a7632054e507d98a54cd3d11573 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate |
2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d042ba5652bd391b57b6ca1bb64b60a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032885fa5400ef95fd2d60def186d989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bee4ae024f81f1d58ebd018177e48819
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75ee027f94411970a967460a9c4b813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f5210c90ee355872d939297b1272b2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0403eaa4a2116ddcda322a860dfb98cc |
| publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019343970-A1 |
| titleOfInvention |
99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| abstract |
The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal 99mTc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical 99mTc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo, the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021217122-A1 |
| priorityDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |